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Background: Obesity and diabetes cause chronic kidney disease with a common
pathophysiology that is characterized by the accumulation of collagen in the extracellular
matrix. Recent evidence has implicated the epithelial-to-mesenchymal transition (EMT)
as a key step in this pathology with regulation by microRNAs. Weight loss leads to
improvements in renal function; therefore, this study hypothesized that bariatric-surgery
aided weight loss would lead to changes in urinary microRNAs involved in the regulation
of renal function.
Materials and methods: Twenty-four bariatric patients undergoing Roux-en-Y gastric
bypass and sleeve gastrectomy donated urine pre-operatively and at 2–6 months and
1–2 years post-operatively. Urine samples were also obtained from 10 healthy weight
and 7 morbidly obese non-surgical controls. Expression levels of kidney microRNAs
were assessed in urine and the function of microRNAs was assessed through the in
vitro transfection of HK-2 cells, a kidney proximal tubule cell line.
Results: Levels of miR 192, miR 200a, and miR 200b were upregulated in urine
following bariatric surgery. This increasewas consistent across surgical type and diabetes
status and was maintained and enhanced with time. Bariatric surgery alters urinary miR
192 expression from levels seen in morbidly obese patients to levels seen in healthy
weight control patients. In mechanistic studies, the transfection of miR 192 in HK-2 cells
increased miR 200a expression and decreased ZEB2, a key transcriptional promoter of
kidney fibrosis.
Conclusions: Bariatric surgery increased miR 192 and miR 200 urinary levels, key
anti-fibrotic microRNAs that could contribute to a renal-protective mechanism and
may be of value as urinary biomarkers following surgery. These findings suggest that
urinary microRNAs may represent potential novel biomarkers for obesity-associated
renal function.
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INTRODUCTION
Whilst obesity contributes to diabetes and hypertension, both
leading causes of progressive chronic kidney disease (CKD),
data suggests that obesity is an independent risk factor for
CKD (1). Diabetes and obesity related CKD appear to share
the same initial pathophysiology (1). Increasing BMI leads to
renal hyperfiltration and proteinuria that eventually culminates
in hypofiltration and CKD. Diabetic nephropathy (DN) occurs
in approximately one third of cases of diabetes (both type
1 and type 2) and is the most common cause of CKD and
end stage renal failure (2). DN is mediated by transforming
growth factor-β1 (TGF-β1) and TGF-β1 promoted fibrosis is
induced by increasing the number of local fibroblasts, which
are the effecter cells in the production and accumulation of
the extracellular matrix. Epithelial-to-mesenchymal transition
(EMT) is increasingly recognized as a key component in this
process by promoting the transition of resident renal epithelial
cells to a fibroblast phenotype (3). Recently, multiple studies have
implicated microRNAs in this process. MicroRNAs are small,
endogenous RNAs that regulate gene expression by silencing the
translation of mRNA. The microRNAs miR 192 and the miR
200 family contribute to kidney fibrosis by suppressing EMT,
targeting zinc E-box binding homeobox 1 and 2 (ZEB1 and
ZEB2) that encode for transcriptional repressors for E-cadherin,
essential for maintaining the epithelial phenotype (4–6). This
leads to an increase in collagen deposition in the extracellular
matrix and the thickening of the glomerular basement, a
common feature of DN.
Weight loss in the clinically obese patient, including
that achieved surgically, leads to an improvement in renal
function (7–9). Bariatric or metabolic surgery encompasses
several gastrointestinal surgical procedures that offer metabolic
modulation to diminish metabolic dysfunction and induce
substantial weight loss through the BRAVE physiological steps–
bile flow alteration, reduction of gastric size, anatomical gut
rearrangement, and altered flow of nutrients, vagal manipulation,
and enteric gut hormone modulation (10). The two most
common bariatric procedures worldwide are the Roux-en-Y
gastric bypass (RYGB) and the sleeve gastrectomy (11). In a
RYGB, a small gastric pouch (15–30mL) is created and separated
from the larger stomach remnant. The jejunum is then incised
from the duodenum and anastomized to the small stomach
pouch forming a distinctive “Y” shape that gives this procedure
its name (12). In a sleeve gastrectomy, a longitudinal gastric
sleeve is created running from the esophagus to the small
intestine that is separated from the larger excised stomach (13). In
comparison to non-surgical strategies, bariatric surgery is more
effective at achieving sustained weight loss, improved quality of
life and increased life expectancy (14, 15). Several studies have
shown that bariatric surgery also leads to remission or resolution
of type 2 diabetes and improved glycaemic control (16–
19). These improvements are observed early post-operatively,
before substantial weight loss and to a greater extent than in
patients who achieve similar weight loss non-surgically, and are
therefore, thought to offer weight-independent metabolic effects
(20, 21) in addition to weight-dependent metabolic actions.
Hypothesizes for this phenomenon include the foregut, hindgut,
and midgut theories (22), but the precise mechanisms behind
improvement of diabetes following bariatric surgery are still not
fully understood. Bariatric surgery also leads to improvements in
cancer risk, sleep apnoea, and other obesity-associated disorders
(23, 24). Thus, bariatric surgery may target and improve renal
function through direct mechanisms of weight loss as well as
through diabetes dependent mechanisms.
MicroRNAs have attracted a great amount of recent attention
as potential novel biomarkers of disease due to their stability
in biofluids and their facile detection through PCR and
profiling platforms (25, 26). Circulating microRNAs are reported
biomarkers for cancer, obesity, and diabetes (25, 27, 28), and
distinct bariatric microRNA profiles have been characterized in
circulation (28, 29). Urinary microRNAs are reported biomarkers
for immunoglobulin A nephropathy and bladder cancer (30,
31). Currently the non-invasive diagnosis of CKD relies on
urinary microalbuminuria and estimated glomerular filtration
rate (eGFR). However, the sensitivity and specificity of these
markers are poor, particularly in obese patients, and only
manifest late in the disease process.
We hypothesized that bariatric surgery modulates the urinary
levels of microRNAs involved in the regulation of renal function.
Therefore, we aimed to study urinary expression of renal
microRNAs in bariatric patients before and after surgery in
comparison to non-surgical control subjects.
MATERIALS AND METHODS
Study Design
Urine samples were collected for 10 healthy weight controls,
seven morbidly obese controls and 24 bariatric surgical patients
in Hull and East Yorkshire Hospitals and Imperial College
Healthcare NHS Trusts under ethics approvals 09/H1304/46 and
08/H0711/123. Informed written consent was provided by all
participants enrolled in this study and all appropriate guidelines
were followed when conducting the methods. For the bariatric
cohort, urine samples were obtained pre-operatively and at two
periods post-operatively–between 2 and 6 months and between
1 and 2 years (Table 1). Nine out of the 24 bariatric patients
had diabetes pre-operatively. Bariatric surgery was performed
laparoscopically. Twenty bariatric patients had a RYGB and four
had a sleeve gastrectomy. All bariatric patients fulfilled NICE
qualifying criteria for bariatric surgery (32). All subjects had
normal serum urea, creatinine, and eGFRs at baseline.
Urinary RNA Extraction
RNA was extracted from 250 µl of urine using the mirVana
PARIS kit (Ambion, Paisley, UK) according to the manufacturer’s
instructions with the one modification; to normalize and for
carrier purposes, 30 femtomoles of synthetic C. elegans miR-39
(Ambion) was spiked into the urine samples prior to the acid-
phenol:chloroform phase. Cel. miR-39 was chosen as carrier as it
lacks sequence homology with human miRNAs. RNA was eluted
in 100 µl nuclease free water.
Frontiers in Endocrinology | www.frontiersin.org 2 May 2019 | Volume 10 | Article 319
Alkandari et al. Bariatric Surgery Modulates Urinary MicroRNAs
TABLE 1 | Study summary.
Controls Bariatric cohort
Healthy Morbidly obese RYGB + Sleeve RYGB Sleeve
n 10 7 24 20 4
Age
†
39.1 (16.3) 54 (11.7) 45.7 (10.8) 45 (10.4) 49.1 (13.7)
Female (n) 8 3 16 14 2
Diabetes (n) 0 1 9 8 1
†
Values represent mean. Standard deviation in parenthesis.
Cell Culture
The human kidney proximal tubule cell (PTC) line HK-2 was
obtained from ATCC (LGC Standards, Teddington, UK) and
maintained in DMEM/Ham’s F12, supplemented with 10% v/v
fetal bovine serum (FBS), 1% Penicillin/Streptomycin antibiotics
(100 U/ml, 100µg/ml, respectively), and 1% Insulin-Transferrin-
Sodium Selenite (Sigma-Aldrich, Gillingham, UK) as previously
described (6).
Transfections
Endogenous microRNA levels were manipulated in HK-2 cells
through the transfection of microRNAmiR 192mimic, a gain-of-
function experiment designed to determine the biological activity
of miR 192. mIRIDIAN microRNA mimics and mimic controls
were purchased from Dharmacon (Lafayette, CO, USA). The
siPORT NeoFX transfection agent was used according to the
manufacturer’s instructions. HK-2 cells at approximately 80%
confluence were trypsinized and seeded at 50,000 cells per well
in complete media in 24 well cell culture plates and transfected
withmiR-192mimic at 10, 20, and 50 nM concentrations for 48 h.
Following SiPORT transfection RNA was extracted from HK-2
cells using the mirVANA PARIS kit according to manufacturer’s
instructions and eluted in 75 µl nuclease free water.
Quantitative PCR
MicroRNAwas reverse transcribed into cDNA using the TaqMan
MicroRNA Reverse Transcription kit (Applied Biosystems,
Paisley, UK) and messenger RNA (mRNA) was reverse
transcribed using the High Capacity Reverse Transcription kit
(Applied Biosystems) according to manufacturer’s instructions.
Relative microRNAs and mRNA levels were determined by real
time, quantitative PCR using TaqMan Fast Universal Master
Mix (Applied Biosystems). Quantitative PCR was performed
in triplicate on the Applied Biosystems 7,500 Fast System. All
PCR and RT probes were obtained from Applied Biosystems.
Urinary microRNA expression was first normalized to creatinine
to correct for diuretic effect (Creatinine Assay, R & D
Systems, Abingdon, UK) and then normalized to cel. miR-39.
Cellular microRNA expression following HK-2 transfections was
normalized to U6 small nuclear RNA and mRNA expression was
normalized to GAPDH, a frequently used housekeeping gene.
Relative expression was calculated using the 2−1Ct method (33).
Statistical Analysis
Urinary microRNA data is expressed as fold change relative to
pre-operative levels or morbidly obese control levels. Data is
represented as mean± standard error of mean (SEM). Statistical
significance was determined using ANOVA (with a post-test
for linear trend) and paired/unpaired Student’s t-test where
appropriate. Significance was considered as p < 0.05. Statistical
analysis was performed using GraphPad Prism 6.0 (Graphpad,
La Jolla, CA, USA).
RESULTS
Bariatric Clinical Outcomes
Bariatric surgery induced substantial clinical improvements in all
bariatric patients (Figure 1). Reduction in BMI was significant
within 100 days of surgery and mean BMI decreased by
almost 30% at 100 days or more after surgery. Mean levels of
fasting blood glucose also decreased following bariatric surgery,
decreasing from 7.5 mmol/L pre-operatively to 5.6 mmol/L 100
days or more following surgery, although this decrease was not
statistically significant. eGFR following bariatric surgery was
unchanged (mean 74–79 mL/min).
Bariatric Surgery Increases Urinary miR
192 Levels
We initially assessed the urinary expression of miR 192, a
consistently abundant renal microRNA (34). In patients who
had laparoscopic RYGB, levels of miR 192 significantly increased
1.3 and 2.9-fold (relative to pre-operative levels) at 2–6 months
and 1–2 years, respectively, following surgery (Figure 2A). A
similar increase was observed in sleeve gastrectomy patients.
MiR 192 levels increased 1.3-fold at 2–6 months following sleeve
procedures and 4.7-fold (significant relative to pre-operative
levels) at 1–2 years post-operatively (Figure 2B). Increase in
urinary miR 192 levels was consistent when patients were
stratified by pre-operative diabetes status. In patients with
diabetes urinary levels of miR 192 increased 1.5-fold at 2–6
months and significantly 3.6-fold at 1–2 years following bariatric
surgery (Figure 2C). Patients without diabetes demonstrated a
significant 2.8-fold increase in miR 192 levels at 1–2 years
following surgery (Figure 2D).
When expressed as fold change relative to the morbidly
obese control group, bariatric pre-operative miR 192 levels were
lower (0.6-fold), potentially reflecting the higher BMI in patients
undergoing bariatric surgery (Figure 3A). Bariatric miR 192
expression was slightly higher 2–6months following surgery (0.8-
fold relative to morbidly obese controls). However, 1–2 years
following bariatric surgery, mean miR 192 level was nearly 2-fold
higher relative to the morbidly obese cohort and was comparable
to miR 192 levels in those with a healthy weight (BMI under 25,
Figure 3A). Although comparative two-way fold changes were
not significant, the linear trend with time was (p = 0.0117,
one-way ANOVA). An inverse correlation between miR 192-fold
change and change in BMI post-operatively was also significant
(p = 0.0342, Pearson’s correlation, Figure 3B). The data show
that bariatric surgery shifts urinary miR 192 expressions from
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FIGURE 1 | Clinical measurements. Pre-operative, post-operative, and control levels of (A) BMI, (B) fasting blood glucose levels and (C) eGFR. Data represent mean
± SEM. *p < 0.05, ****p < 0.0001 by Student’s t-test.
FIGURE 2 | Urinary miR 192 expression following bariatric surgery. (A) RYGB patients. (B) Sleeve gastrectomy patients. (C) Patients with diabetes. (D) Patients
without diabetes. Data represents mean fold change ± SEM relative to mean preoperative expression. n = 20 for RYGB, n = 4 for sleeve, n = 9 for diabetes, and
n = 15 for individuals without diabetes. Each patient is represented by a unique symbol. *p < 0.05 vs. preoperative expression by paired t-test.
levels observed in a morbidly obese population to levels observed
in a healthy weight population.
Of the 24 individuals who made up the bariatric cohort,
20 had increased urinary miR 192 expression post-operatively
relative to their pre-operative levels, including 16 out of the 20
RYGB patients, eight out of nine patients with diabetes and all
four sleeve gastrectomy patients. A timecourse of post-operative
miR 192 expressions in RYGB and sleeve patients relative to
their individual pre-operative miR 192 levels can be found
in Figure 3C. A significant correlation was found between
individual, personalized fold changed in miR 192 levels and
days following surgery (p = 0.0051, Pearson’s correlation).
This illustrated a trend of a gradual, general increase in miR
192 levels in urine which is enhanced and sustained with
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FIGURE 3 | Bariatric urinary miR 192 expression relative to a morbidly obese cohort. (A) Bariatric and healthy weight miR 192 expression relative to a morbidly obese
control group. Data represents mean ± SEM relative to mean preoperative expression. Morbidly obese is a BMI ≥ 40 kg/m2, healthy weight is a BMI < 25 kg/m2.
n = 7 for morbidly obese, n=10 healthy weight, n = 24 for preoperatively, 2–6 months and 1–2 years post-operatively. (B) Pearson correlation of miR 192-fold change
against change in post-operative BMI. n = 46. (C) Timecourse of miR 192 expression following surgery. Data represented as fold change relative to individual
preoperative expression for 24 bariatric patients.
time and consistent with migration toward the healthy weight
control phenotype.
Bariatric Surgery Increases Urinary Levels
of miR 200a and miR 200b
Urinary levels of miR 200a and miR 200b were also measured.
Both are expressed in the kidney and change in their expression
is associated with diabetic nephropathy (5, 6). MiR 200a urine
levels increased 2.5-fold at 2–6 months and 3.4-fold at 1–2
years following surgery (Figure 4A), although neither increase
achieved statistical significance. MiR 200b levels increased 5.8-
fold at 2–6months and strikingly 28.6-fold (significantly different
from the pre-surgery levels) at 1–2 years post-operatively
(Figure 4B). All but one patient demonstrated a post-operative
increase of urinary miR 200a and all patients demonstrated an
increase in urinary miR 200b relative to their individual pre-
operative level. Significant correlations were observed between
both miR 200a and miR 200b and days following bariatric
surgery (Figures 4C,D, p = 0.0071 and 0.044, respectively,
Pearson’s correlation). There were also significant correlations
between urinary levels of miR 192 and both miR 200a and miR
200b (Supplementary Figure 1, p = 0.0364 and p < 0.0001,
respectively, Pearson’s correlation).
Mechanistic Studies in the Human PTC
Line, HK-2
To explore the mechanistic implications of altered microRNA
expression following bariatric surgery, we used the human
PTC HK-2 renal cell line to examine changes in phenotype.
Transfection with all three concentrations of miR 192 mimic
increased miR 192 expression 4,000, 16,000, and 18,000-fold,
respectively, relative to cells transfected with a scrambled control
(Figure 5A). Transfection of miR 192 increased levels of miR 200
at all concentrations, although the increase was only significant
at 10 nM (Figure 5B). Expression levels of ZEB1 and Colα1
were unaltered for all three miR 192 mimic concentrations
(Figures 5C,E). However, transfection with 50 nM miR 192
mimic concentration resulted in a significant 0.6-fold decrease in
ZEB2 (Figure 5D).
DISCUSSION
There is a growing body of evidence that biofluid miRNA
expression can be indicative of disease progression and
prognosis (35–37). Urinary expression of microRNAs has also
been proposed as useful in the diagnosis and prognosis of
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FIGURE 4 | Urinary expression of miR 200 following bariatric surgery. (A) miR-200a, n = 9 (B) miR-200b, n = 8. Data represents mean fold change ± SEM relative to
mean preoperative expression. **p < 0.01 vs. preoperative expression by paired t-test. Each patient is represented by a unique symbol. Timecourse of (C) miR 200a
and (D) miR 200b expression following surgery. Data represented as fold change relative to individual preoperative expression.
renal disease (38). We therefore considered whether bariatric
surgery modulates urinary levels of miRNAs that regulate
kidney function.
Three kidney-expressed microRNAs, miR 192, miR 200a, and
miR 200b, were shown to be upregulated in urine following
bariatric surgery, an increase that was consistent across surgical
type and diabetes status and was sustained and enhanced with
time. Bariatric surgery shifts urinary miR 192 expression from
levels seen in morbidly obese patients to levels comparable
with those seen in a healthy cohort. In mechanistic studies,
the transfection of miR 192 in a human kidney PTC cell line
increased miR 200a and decreased ZEB2, a key transcriptional
promoter of kidney fibrosis. These three microRNAs assessed
in urine could potentially represent non-invasive, anti-fibrotic
biomarkers for surgery-induced improvement in renal function.
The kidney-specific deletion of Dicer, a ribonuclease involved
inmicroRNAbiogenesis, leads to proteinuria, glomerular disease,
and tubular injury in mice (39–41). This illustrates the important
functional roles of microRNAs in kidney pathophysiology. MiR
192 is one of 5 microRNAs whose expression is higher in the
kidney relative to other organs (34), and its levels are reduced
in human renal biopsies from patients with advanced diabetic
nephropathy, levels that correlate with tubulointerstitial fibrosis,
and decreased GFR, reflecting miR 192’s key anti-fibrotic role
(6). In vitro incubation of PTCs with TGF-β1 decreases miR
192 expression and the overexpression of miR 192 suppresses
ZEB1 and ZEB2, decreasing TGF-β1 mediated E-cadherin
suppression (6). In diabetic apoE mice, miR 192 expression
was downregulated in the kidney and treatment of PTCs with
TGF-β1 results in a reduction of miR 192 (42). Renal levels of
the miR 200 family are decreased in mouse models of renal
scarring and by TGF-β1 in rat PTCs (43). Injection of miR 200b
precursor antagonizes ZEB1/ZEB2 induction, decreases collagen
synthesis, and ameliorates fibrosis (44). p53 tumor suppressor
increases expression of miR 192 and miR 200, suppressing EMT
(45). It has also been reported that miR 200 expression is a
strong biomarker for epithelial vs. mesenchymal phenotype in
cancer (46). MiR 200 overexpression results in mesenchymal to
epithelial transition in mouse carcinomas and overexpressing
miR 200 in vitro increases E-cadherin and represses EMT (4, 5).
Here, miR 192 transfection of human PTCs led to an increase in
miR 200a, indicating that miR 192 could act upstream tomiR 200
in a hierarchical regulation pathway, suggestingmiR 192may be a
master microRNA regulator in the kidney (Figure 6). Previously
miR 192 has been shown to upregulate miR 200b/c expression in
mesangial cells (47).
In contrast to their roles in PTCs, miR 192, and miR 200
appear to have pro-fibrotic effect in mesangial cells. TGF-β1
increases miR 192 in mouse mesangial cells and repression of
ZEB1/ZEB2 expression by miR 192 leads to collagen synthesis
(48). The inhibition of miR 192 in streptozotin-induced diabetic
mice reduces proteinuria (49). In mesangial cells, miR 200 family
represses ZEB1/ZEB2, promoting fibrosis (47). The pleiotropic,
cell-specific roles miR 192 and miR 200 play in renal fibrosis
reflect the complex physiology of the kidney. Indeed, the renal
cortex and the medulla have different microRNA expression
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FIGURE 5 | miR 192 mimic transfection of HK2 cells illustrates its anti-fibrotic role. Expression of (A) miR 192 (B) miR 200a (C) ZEB1 (D) ZEB2 and (E) Colα1
following 48 h of 10, 20, and 50 nM miR 192 mimic transfection. Data represents mean ± SEM relative to transfection with a scrambled control. *p < 0.05,
***p < 0.001, ****p < 0.0001, n = 3.
profiles (50). It is worth noting that proximal tubular cells
are further along the urinary tract than mesangial cells of the
glomerulas and that urinary levels of miR 192 and miR 200
are decreased in patients with bladder cancer, correlating with
increased EMT (31).
In this study patients had normal renal function and therefore
a change in renal function following surgery was not expected.
However, other studies have reported improvements in renal
function following bariatric procedures. Weight loss is associated
with a reduction in proteinuria, including weight loss achieved
surgically (7–9). Bariatric surgery improves renal function in
patients with pre-existing glomerular hyperfiltration (9). Surgery
also leads to reduced levels of albuminuria 1 year post-
operatively, and levels continue to decrease up to 2 years and
were maintained up to 5 years post-surgery (51, 52). Remission
of microalbuminuria in individuals with diabetes can reach 60%
5 years following surgery. Surgery also has preventive effects,
reducing the incidence of microalbuminuria by 80% and diabetic
nephropathy by 60% compared to patients treatedmedically (52).
Bariatric surgery can also lead to improvement and remission
in patients with established CKD (53). The results presented
here suggest miR 192 may mediate these renal improvements
following bariatric surgery.
The early detection of DN is important in preventing
progression to renal failure and there are considerable limitations
of conventional markers of kidney function. Novel markers
of DN have been reported, including proteins, peptides, and
growth factors (54). Several studies have reported distinct
microRNA profiles in urine, urinary sediments, and circulation
in cases of kidney diseases. Urinary miR 29b, miR 29c, and
miR 93 levels are correlated with proteinuria and renal scarring
in patients with IgA nephropathy (55). Urinary microRNA
profiles can also be used to differentiate various stages of
diabetic nephropathy in individuals with type 1 diabetes (35).
MicroRNA 145 is upregulated in the urinary exosomes of type
1 diabetes patients with microalbuminuria (56) and urinary
microRNA levels, including levels of miR 192, can predict
the development of microalbuminuria (57). In circulation,
increased levels of miR 25, miR 27, miR 152, and miR
182 has been reported in patients with type 1 diabetes (58),
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FIGURE 6 | The renal function of miR 192 and miR 200. (Left) Mechanism for
glucose-mediated renal fibrosis in the proximal tubular cells. Diabetes
increases TGF-β which inhibits miR 192/200, lifting the suppression on ZEB
and EMT. (Right) Suggested mechanism following bariatric surgery.
and a recent report identified 10 elevated and two lowered
microRNAs in patients with diabetes with DN relative to
healthy controls (59). Circulating microRNAs can select diabetes
patients with DN from those with good renal function,
suggesting prognostic potential (59). This has led to interest
in microRNAs as potential novel drug targets. The successful
manipulation of miR 192 expression in the renal cortex of
normal and diabetic mice (60) suggests the same may be possible
in humans.
Other microRNAs have been reported to be involved in
DN, including miR 21, miR 25, and miR 29 (61–63). The
expression of more microRNAs needs to be assessed in bariatric
urine samples and validated in vitro. However, there are
limitations to using in vitro models of renal function, as
EMT is more commonly observed in immortalized cell lines
than in vivo renal fibrosis (64). The role of microRNAs in
mediating the post-bariatric improvements in renal health needs
to be confirmed in larger, prospective, multi-centre studies of
bariatric patients including cohorts with varying degrees of
kidney dysfunction.
In summary, bariatric surgery increased the urinary
expression of the anti-fibrotic microRNAs miR 192 and miR 200
to levels found in the healthy controls. Several recent studies have
assessed the suitability of urinary microRNAs as biomarkers,
given the clinical ease of collecting and analyzing samples and the
limitation of conventional markers of renal function. This study
highlights the potential of urinary microRNAs as non-invasive
biomarkers of health following bariatric surgery.
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